On 16 November 2022, the medical journal CELL published a study under the signature of, among others, Fauci, entitled : " Rethinking next-generation vaccines for coronaviruses and other respiratory viruses "
The first word of the title lets you guess what the study is about.
" Rethinking " or " what exists is worth nothing, we have to come up with something else ". This is exactly what the study states in veiled terms.
Some of the views of Fauci and co-researchers.
A. INFLUENZA
" Until the emergence of COVID-19, influenza was for many decades the deadliest vaccine-preventable viral respiratory disease, for which only less than suboptimal vaccines are available."
"Over the years, influenza vaccines have never been able to elicit sustained protective immunity against seasonal influenza virus strains, even against non-spread strains"
"As of 2022, after more than 60 years of experience with influenza vaccines, very little improvement has been observed in the prevention of infection by vaccines."
"As noted decades ago, and still today, the effectiveness rates of our best approved flu vaccines are inadequate for licensing most other vaccine-preventable diseases.
Even decades of efforts to develop better, so-called "universal" flu vaccines - vaccines that would create broader protective immunity, preferably with a longer duration have not yet resulted in next-generation broadly protective vaccines, although a large number of experimental vaccines are in preclinical or early clinical development "
So ... there is no such thing as efficient flu vaccines. Only " less than sub-optimal " vaccines which is as good as saying they are inferior and serve no purpose. So why vaccinate anyway ?
2. COVID & RSV
" As variants of SARS-CoV-2 have emerged, shortcomings in these vaccines reminiscent of flu vaccines have come to light.
"Vaccines for these two very different viruses share common characteristics: they provide incomplete and short-lived protection against evolving virus variants that escape population immunity.
"Since vaccine development and licensing is a long and complex process that requires years of pre-clinical and clinical data on safety and efficacy, the limitations of influenza and SARS-CoV-2 vaccines remind us that candidate vaccines for most other respiratory viruses have so far failed to provide sufficient protection to qualify for licensing, including candidate vaccines against RSV,"
" Not surprisingly, none of the predominantly mucosal respiratory viruses have ever been effectively controlled by vaccines. This finding raises a fundamental question: if natural mucosal infections with respiratory viruses do not induce full and long-term protective immunity against reinfection, how can we expect vaccines, especially systemically administered non-replicating vaccines, to do so? This is a major challenge for future vaccine development, and overcoming it is crucial for the development of 'next-generation' vaccines."
So ... the Covid vaccines and all the others are also not working, or at least not as we might expect. New-generation vaccines need to be developed, according to Fauci, which is the challenge of the future.
This is confirmed by an established practice. Meanwhile, the purported vaccination has become an ongoing medical treatment whereas people continue to get seriously ill and die ( mainly in the vaccinated group ).
C. FURTHER RESEARCH
" In general, and if feasible, mucosal immunisation seems to be the optimal approach for respiratory viruses"
( note : mucosal immunisation is the body's first natural line of defence against infections or preemptive desensitisation against a given infection via vaccines or serums ).
" However, when considering next-generation vaccines, we may also need optimised formulations, higher vaccine doses, increased vaccine administration frequency and overcoming immune tolerance challenges.
( note : so Fauci knows that vaccines can cause immune problems, the existing vaccines are not satisfactory in any respect and vaccines of the future generation will also need to be administered more frequently and at a higher dose )
" It is important for any virus to answer key questions such as:
(1)
Can non-replicating vaccines, which can be significantly less effective in inducing IgA, be as effective as replicating vaccines, such as live attenuated virus vaccines and live vaccine vectors expressing key viral proteins?
(2)
Can mono- or pauci antigen vaccines provide protection equivalent to more antigenically complex vaccines?
(3)
Can higher antigen doses or repeated vaccinations induce better immunity?
(4)
What are the differential effects of soluble versus particulate antigens?
(5)
What are ideal relationships between the amount of antigen in the vaccine and systemic or mucosal adjuvantisation?
(6)
What are the optimal strategies for routes and timing of vaccination: mucosal/systemic "prime-boost"? Newer strategies such as "prime-pull" and "prime-deploy" (vaccination strategies to elicit systemic T-cell responses followed by recruitment of activated T cells via a decoy or recruitment of resident memory T cells, respectively to the lung, and other ?
( note : apparently, science does not yet know the answer to all these questions while 8 billion doses of the existing vaccine already administered in the meantime. Moreover, it is not demonstrated that and why mucosal immunisation is better than natural immunisation. The first option is preferred. Why ?Because there is a lot of money to be made with vaccines while the second option yields nothing )
D. TESTSUBJECTS AND VACCINE HOSTS
" Vaccinated hosts and risk groups are numerous and heterogeneous.
A key challenge for next-generation vaccines is to determine whether one-size-fits-all vaccines or vaccines targeted at key risk groups will be useful. Inevitably, different human risk groups will need different vaccines or vaccine formulations. For example, we know that RSV infections are best prevented by humoral immunity in children, but by cell-mediated immunity in the elderly.
Moreover, children may need different vaccine doses from young adults, who in turn may need different doses from the elderly with a limited B-cell and especially T-cell repertoire for viral antigens.
Indeed, it seems likely that respiratory vaccines that do not elicit robust cell-mediated immunity may be suboptimal for the elderly - but also that vaccines that elicit stronger cell-mediated responses may increase the risk of immunopathogenic effects. If so, can optimal trade-offs be found? Elderly people are the most important risk group for vaccine prevention of influenza, SARS-CoV-2, RSV and other respiratory viruses, because they are most likely to suffer severe and fatal consequences and are least likely to respond to vaccination. It will also be important to find out more about genetic differences between individuals with regard to viral mucosal antigen detection, predisposition to severe disease and vaccine protection; for example, variations in IFITM3 and and other IFN pathway-associated genes, as there is much evidence that severe viral respiratory disease often reflects host genetic susceptibility factors."
( note : so, they have known all along that children were neither at risk nor causing it and elderly + 65 years were the main risk groups, which by the way was already put in writing in The Joint Commission's report of 25.02.2020 AND also in The Great Barrington Declaration signed by more than 6,0000 doctors and scientists. Why then have all other age groups been vaccinated with a product that does not do what it promises, causes many side-effects with potentially fatal results, about which, moreover, steely lies have been persistently told ? Are all people test subjects or " vaccine hosts " ? )
E. THE FUTURE ?
" Once improved vaccines are developed, vaccine formulations and schedules will have to be optimised to elicit the best sustained protective mucosal immunity, especially with multivalent or amplified vaccines, for which the immunodominance of antigens and the balance between humoral and cell-mediated immune responses can be complex.
In terms of public health utility and acceptance, it will be important to consider the role of vaccines with high-dose or frequent boost antigens, and mixed sequential vaccines (e.g. prime-boost with different vaccines), and whether these approaches will be accepted by providers, regulators and the public.
The observation that repeated exposure of infants to RSV reduces severe disease in later infection combined with experimental data suggest that the timing and frequency of respiratory vaccines may be important.
Indeed, a recent controversial theory suggests that the most important determinant of immune/vaccine protection is not immune memory and recall, but repeated antigenic exposures.
This proposal seems to be contradicted by many observable phenomena, but at the same time is consistent with the observation that the retention of memory T cells in the lungs is associated with repeated antigenic exposures.
Because of its implications for vaccinology, this question can and should be studied experimentally. It also requires reconsideration of many accepted approaches, such as a single annual influenza vaccination at the beginning of the flu season.
We should also ask whether other vaccine approaches should be considered, such as consecutive seasonal vaccinations and additional mucosal vaccines to boost specific upper respiratory immunity or non-specific innate immunity. Such approaches could include, for example, prime-boost approaches, combining systemic and mucosal immunity, perhaps with an initial systemic vaccination followed by a boost with intranasal vaccination or vice versa.
Besides intranasal vaccination, we will need to better investigate the response to vaccination in other respiratory immune compartments, such as conjunctival eye drop vaccination and especially aerosol vaccination for certain respiratory viruses, as suggested in human and animal experimental studies for influenza and other respiratory viral diseases."
E. CONCLUSION
" Durable protective vaccines against high-mortality non-systemic mucosal respiratory viruses have not been developed so far.
The challenges for developing a new generation of respiratory vaccines are numerous and complex (Table 2). We need to better understand why multiple consecutive mucosal infections with the same circulating respiratory viruses, spread over decades of life, do not induce natural protective immunity, especially in viruses that do not show significant antigenic drift (e.g. RSV and parainfluenza viruses)
if we are to rationally develop vaccines to prevent them.
We need to think outside the box to create next-generation vaccines that induce immune protection against viruses that survive in human populations because they may remain significantly outside the full protection range of innate and adaptive human immunity.
Past attempts to provide robust protection against mucosal respiratory viruses and to control the deadly outbreaks and pandemics they cause have failed scientifically and public health-wide and need to be addressed urgently.
We are pleased and encouraged that many researchers and collaborative groups are rethinking all our past assumptions and approaches to the prevention of major viral respiratory diseases from the ground up and working on bold new ways forward."
Well, that's clear. This is not something Fauci & co only found out about in November 2022. They knew it from the start. The world has been tricked, lied to and deceived.
Spikes gevonden in de kankercel Bioweapon
https://rumble.com/v28tg6i-cancer-rates-explode-from-vaxx-mrna-spike-protein-found-in-center-of-canc